Published by Josh White on 5th November 2025
(Sharecast News) - Hutchmed China said in an update on Wednesday that it has completed patient enrollment for its global phase three 'Saffron' trial evaluating the combination of Orpathys and Tagrisso in certain lung cancer patients with MET overexpression or amplification who had progressed following Tagrisso treatment.